Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.

Abstract

11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) has been a target of intensive research efforts across the pharmaceutical industry, due to its potential for the treatment of type II diabetes and other elements of the metabolic syndrome. To demonstrate the value of 11β-HSD1 in preclinical models, we required inhibitors with good potency against both human and… (More)
DOI: 10.1021/jm3013163

Topics

Cite this paper

@article{Goldberg2012FreeWilsonAS, title={Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.}, author={Frederick W Goldberg and Andrew G Leach and James S Scott and Wendy L Snelson and Sam D Groombridge and C. J. S. Donald and Stuart N L Bennett and Cristian Bodin and Pablo Gutierrez and Amy C Gyte}, journal={Journal of medicinal chemistry}, year={2012}, volume={55 23}, pages={10652-61} }